Lentinan

Из Википедије, слободне енциклопедије
Lentinan
(IUPAC) ime
β-D-glukopiranozil-(1→6)-[β-D-glukopiranozil-(1→3)-[β-D-glukopiranozil-(1→6)]-β-D-glukopiranozil-(1→3)-β-D-glukopiranozil-(1→3)β-D-glukopiranozil-(1→3)]-β-D-glukopiranoza
Klinički podaci
AHFS/Drugs.com Internacionalno ime leka
Identifikatori
CAS broj 37339-90-5
ATC kod L03AX01
PubChem[1][2] 37723
KEGG[3] D01695 YesY
Hemijski podaci
Formula C42H72O36 
Mol. masa 1152.99948 g/mol
Sinonimi (2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6S)-3,5-dihidroksi-2-(hidroksimetil)-6-[(2R,3R,4S,5R,6R)-2,3,5-trihidroksi-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihidroksi-6-(hidroksimetil)oksan-2-il]oksimetil]oksan-4-il]oksioksan-4-il]oksi-3,5-dihidroksi-6-(hidroksimetil)oksan-4-il]oksi-3,5-dihidroksi-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihidroksi-6-(hidroksimetil)oksan-2-il]oksimetil]oksan-4-il]oksi-6-(hidroksimetil)oksan-3,4,5-triol
Farmakoinformacioni podaci
Trudnoća  ?
Pravni status

Lentinan je beta-glukan sa glikozidnim β-1,3:β-1,6 vezama.[4] On je antitumorni polisaharid iz šitake (Lentinula edodes) pečurke.[4] Lentinan je polisaharid sa molekulskom težinom od oko 500.000 Da. Japanska farmaceutska kompanija Ajinomoto je razvila lek Lentinan, koji se intravenozno dozira kao agens protiv kancera.[5]

Lentinan je jedan od lekova protiv kancera[6] za koji je pokazano da utiče na odbrambeni imunski sistem domaćina.[7]

Klinička israživanja na obolelima od raka su ukazala na vezu između lentinana i povišenog stepena perživljavanja, poboljšanog kvaliteta života, i umanjene ponovne pojave kancera.[8][9][10][11][12][13][14][15]

Reference[уреди]

  1. ^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.“. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. ^ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities“. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. ^ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG“. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H. 
  4. ^ а б Cancer Guide Includes many abstracts
  5. ^ „Medicinal Mushrooms:Their therapeutic properties and current medicalusage with special emphasis on cancer treatments“. 
  6. ^ Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.“. Hepatogastroenterology 46 (28): 2662–8. PMID 10522061. 
  7. ^ Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group“. Hepatogastroenterology 46 (28): 2662–8. PMID 10522061. 
  8. ^ Yang P, Liang M, Zhang Y, Shen B. (Aug 2008). „Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC.“. Adv Ther. 25 (8): 787–94. DOI:10.1007/s12325-008-0079-x. PMID 18670743 
  9. ^ Nimura H, Mitsumori N, Takahashi N, (Jun 2006). „[S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer]“. Gan to Kagaku Ryoho. 33 (1): 106–9. PMID 16897983 
  10. ^ Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K. (1999). „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.“. Hepatogastroenterology. 46 (28): 2662–8. PMID 10522061 
  11. ^ Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J (July 2009). „Individual Patient Based Meta-analysis of Lentinan for Unresectable/Recurrent Gastric Cancer“. Anticancer Res. 29 (7): 2739–45. PMID 19596954. 
  12. ^ Hazama S, Watanabe S, Ohashi M, et al. (July 2009). „Efficacy of Orally Administered Superfine Dispersed Lentinan ({beta1,3-Glucan) for the Treatment of Advanced Colorectal Cancer“. Anticancer Res. 29 (7): 2611–7. PMID 19596936. }-
  13. ^ Kataoka H, Shimura T, Mizoshita T, et al. (2009). „Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life“. Hepatogastroenterology 56 (90): 547–50. PMID 19579640. 
  14. ^ Isoda N, Eguchi Y, Nukaya H, et al. (2009). „Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma“. Hepatogastroenterology 56 (90): 437–41. PMID 19579616. 
  15. ^ Shimizu K, Watanabe S, Watanabe S, et al. (2009). „Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer“. Hepatogastroenterology 56 (89): 240–4. PMID 19453066. 

Literatura[уреди]

Vidi još[уреди]

Spoljašnje veze[уреди]

  • Lentinan effects (antitumor and others)